Researchers from Canwell Biotech Ltd. presented preclinical data for CAN-2109, a novel long-acting immunogenic cell death inducer being developed for the treatment of cancer.
Astellas Pharma Inc. presented the first preclinical data on ASP-1002, a bispecific antibody targeting claudin-4 (CLDN4) and CD137, for the treatment of patients with metastatic or locally advanced solid tumors.
Antibody-drug conjugates (ADCs) combine monoclonal antibody-targeting capabilities with the cytotoxic effect of conjugated drug payloads. However, there is a need for enhanced strategies to overcome restricted therapeutic window or unacceptable off-target effects.
Evolveimmune Therapeutics Inc. has unveiled EVOLVE-205, a new 2:1 T-cell engager targeting CD20 with integrated affinity-tuned CD3 and CD2 agonists to promote anti-B-cell immunity.
At the Society for Immunotherapy of Cancer (SITC) meeting that ended yesterday in Houston, Dragonfly Therapeutics Inc. reported the first preclinical data on DF-6215, an alpha-active IL-2-Fc, for cancer immunotherapy.
